Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
BACKGROUND:Cetuximab and panitumumab are monoclonal antibodies targeting the epidermal growth factor receptor. Both drugs are active against RAS wild type metastatic colorectal cancer after chemotherapy failure, with similar efficacy and toxicity profiles. However, their cost and limited survival be...
| প্রধান লেখক: | , , |
|---|---|
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | English |
| প্রকাশিত: |
Public Library of Science (PLoS)
2017-01-01
|
| মালা: | PLoS ONE |
| অনলাইন ব্যবহার করুন: | http://europepmc.org/articles/PMC5389795?pdf=render |